Clinical differences between elderly-onset and non-elderly-onset ulcerative colitis: A nationwide survey data in Japan.

Clinical differences between elderly-onset and non-elderly-onset ulcerative colitis: A nationwide survey data in Japan. J Gastroenterol Hepatol. 2018 Apr 18;: Authors: Komoto S, Higashiyama M, Watanabe C, Suzuki Y, Watanabe M, Hibi T, Takebayashi T, Asakura K, Nishiwaki Y, Miura S, Hokari R Abstract OBJECTIVE: Studies on the characteristics of elderly-onset ulcerative colitis (EOUC) and non-elderly-onset UC (NEOUC) have reported conflicting findings. The aim of this study was to compare disease characteristics of EOUC and NEOUC by analyzing the database of the Japanese nationwide inflammatory bowel disease (IBD) registry. STUDY…

Read More

Predictors and clinical outcomes of follow-up loss in patients with inflammatory bowel disease.

Predictors and clinical outcomes of follow-up loss in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2018 Apr 17;: Authors: Woo DH, Kim KO, Kang MK, Lee SH, Jang BI, Kim TN Abstract BACKGROUND AND AIM: Nonadherence is a risk factor of disease worsening in inflammatory bowel disease (IBD). We analyzed the frequency, predictors, and clinical outcomes of patients with IBD who are lost to follow-up in outpatient clinics. METHODS: Medical records of 784 IBD patients visiting our IBD clinic between January 2010 and December 2015 were reviewed retrospectively. Overall,…

Read More

Clinical and genetic risk factors for decreased bone mineral density in Japanese patients with inflammatory bowel disease.

Related Articles Clinical and genetic risk factors for decreased bone mineral density in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2018 Mar 30;: Authors: Naito T, Yokoyama N, Kakuta Y, Ueno K, Kawai Y, Onodera M, Moroi R, Kuroha M, Kanazawa Y, Kimura T, Shiga H, Endo K, Nagasaki M, Masamune A, Kinouchi Y, Shimosegawa T Abstract BACKGROUND AND AIM: Patients with inflammatory bowel disease (IBD) are at a high risk of low bone mineral density (BMD). Reportedly, clinical and genetic factors cause low BMD in Caucasians; however,…

Read More

Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician.

Related Articles Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. J Gastroenterol Hepatol. 2018 Mar 30;: Authors: Miehlke S, Acosta MB, Bouma G, Carpio D, Magro F, Moreels T, Probert C Abstract Oral budesonide is a second- generation steroid which allows local, selective treatment of the gastrointestinal tract and the liver, minimizing systemic exposure. The results of randomized trials comparing budesonide versus placebo or active comparators have led to expert recommendations that budesonide be used to treat mild or moderate active ileocecal Crohn’s disease, microscopic…

Read More

Roseburia intestinalis alleviates experimental colitis pathology by inducing anti-inflammatory responses.

Roseburia intestinalis alleviates experimental colitis pathology by inducing anti-inflammatory responses. J Gastroenterol Hepatol. 2018 Mar 12;: Authors: Shen Z, Zhu C, Quan Y, Yang J, Yuan W, Yang Z, Wu S, Luo W, Tan B, Wang X Abstract BACKGROUND AND AIM: To elucidate the anti-inflammatory effect and mechanism of Roseburia intestinalis (R.intestinalis) in Crohn’s disease (CD). METHODS: 16S-rRNA genome sequencing technique is used to detect the characteristics of intestinal microbiota in untreated CD patients and healthy controls. Then we investigate the effects of R.intestinalis on disease activity index (DAI) score,…

Read More

Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol. 2018 Mar 07;: Authors: Takedatsu H, Mitsuyama K, Fukunaga S, Yoshioka S, Yamauchi R, Mori A, Yamasaki H, Kuwaki K, Sakisaka H, Sakisaka S, Torimura T Abstract BACKGROUND AND AIM: Proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCAs) are well-known serological markers for granulomatosis with polyangiitis, but their role as serological markers for inflammatory bowel disease (IBD) remains uncertain. The present study aimed to evaluate the diagnostic and clinical role of PR3-ANCAs as markers…

Read More

A comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis.

A comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis. J Gastroenterol Hepatol. 2018 Feb 20;: Authors: Hirano A, Umeno J, Okamoto Y, Shibata H, Ogura Y, Moriyama T, Torisu T, Fujioka S, Fuyuno Y, Kawarabayasi Y, Matsumoto T, Kitazono T, Esaki M Abstract BACKGROUND AND AIM: The gut microbiota is suggested to play an important role in the pathogenesis of ulcerative colitis (UC). However, inter-individual and spatial variations hamper the identification of UC-related changes. We thus investigated paired mucosa-associated microbiota obtained from…

Read More

Crohn’s Disease associated Strictures.

Crohn’s Disease associated Strictures. J Gastroenterol Hepatol. 2018 Feb 10;: Authors: Wo WCP, Mourad F, Leong RWL Abstract Crohn’s disease (CD) is a chronic relapsing and remitting disease that can affect any segments of the gastrointestinal (GI) tract. More than 50% of patients with CD develop stricturing or penetrating complications within the first 10 years after diagnosis. Strictures can lead to intestinal obstruction, which is a common indication for surgery. Despite significant advances in the understanding of the pathogenesis of intestinal fibrostenosis, imaging and therapeutic armamentarium of CD, the risk…

Read More

Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis.

Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2018 Feb 10;: Authors: Dai C, Jiang M, Sun MJ, Cao Q Abstract OBJECTIVE: Fecal immunochemical test (FIT) is a promising marker for assessment of inflammatory bowel disease (IBD) activity. However, the utility of FIT for predicting mucosal healing (MH) of Ulcerative Colitis (UC) patients has yet to be clearly demonstrated. The objective of our study was to perform a diagnostic test accuracy test meta-analysis evaluating the diagnostic accuracy of FIT…

Read More
<< Go Back